United States - English - NLM (National Library of Medicine)

csl behring ag - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 12.5 g in 50 ml - since the oncotic pressure of alburx® 25, albumin (human) 25% solution is about four times higher than that of normal human serum, it will expand the plasma volume if interstitial water is available for an inflow through the capillary walls. however, many patients suffering from an acute volume deficit also have some degree of interstitial dehydration. in the absence of hyperhydration, the treatment of an acute volume deficit with alburx® 25 should therefore include isotonic electrolyte solutions with an albumin:electrolyte ratio of 1:3 or 1:4. by contrast, chronic volume deficits have usually been at least partially compensated for by the renal retention of sodium and water with some degree of tissue edema, and in these circumstances a trial with alburx® 25 only is indicated. in any case, an anemia of clinically relevant magnitude requires specific treatment, and the metabolic needs of the patient with respect to fluid and electrolytes must be cared for. the common causes of hypoproteinemia are protein-ca

United States - English - NLM (National Library of Medicine)

kedrion biopharma, inc. - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - emergency treatment of hypovolemic shock albuked 25 is hyperoncotic and on intravenous infusion will expand the plasma volume by an additional amount, three to four times the volume actually administered, by withdrawing fluid from the interstitial spaces, provided the patient is normally hydrated interstitially or there is interstitial edema.(1) if the patient is dehydrated, additional crystalloids must be given,(4) or alternatively, albumin (human) 5%, usp (albuked™ 5) should be used. the patient’s hemodynamic response should be monitored and the usual precautions against circulatory overload observed. the total dose should not exceed the level of albumin found in the normal individual, i.e., about 2 g per kg body weight in the absence of active bleeding. although albuked 5 is to be preferred for the usual volume deficits, albuked 25 with appropriate crystalloids may offer therapeutic advantages in oncotic deficits or in long-standing shock where treatment has been delayed.(2) removal of ascitic fluid from a

Israel - English - Ministry of Health

kamada ltd, israel - albumin human - solution for infusion - albumin human 200 mg/ml - albumin - albumin - for restoration and maintenance of circulating blood volume where volume deficiency has been demontrated and use of a colloid such as albumin is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient based on official recommendations.

United States - English - NLM (National Library of Medicine)

grifols usa, llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 12.5 g in 50 ml - for restoration and maintenance of circulating blood volume where hypovolemia is demonstrated and colloid use is appropriate. when hypovolemia is long standing and hypoalbuminemia exists accompanied by adequate hydration or edema, 20-25% albumin solutions should be used.1,2,3 acute liver failure is a special situation in which both hypovolemia and hypoalbuminemia can be present. human albumin grifols® 25% can be used in such cases.1 human albumin grifols 25% may be of value in the treatment of shock or hypotension in renal dialysis patients.1 preoperative dilution of blood using albumin and crystalloid can be used in cardiopulmonary bypass procedures. albumin also may be used in the priming fluid.4,5,6 human albumin grifols 25% may be used to treat peripheral edema in patients with acute nephrosis who are refractory to cyclophosphamide, corticosteroid therapy or diuretics.1,2,7 human albumin grifols 25% may be indicated for subjects with hypoalbuminemia who are critically ill and/or actively bleeding. when

United States - English - NLM (National Library of Medicine)

grifols usa, llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - emergency treatment of hypovolemic shock plasbumin-20 is hyperoncotic and on intravenous infusion will expand the plasma volume by an additional amount, three to four times the volume actually administered, by withdrawing fluid from the interstitial spaces, provided the patient is normally hydrated interstitially or there is interstitial edema.(1) if the patient is dehydrated, additional crystalloids must be given,(4) or alternatively, albumin (human) 5%, usp (plasbumin® -5) should be used. the patient’s hemodynamic response should be monitored and the usual precautions against circulatory overload observed. the total dose should not exceed the level of albumin found in the normal individual; i.e., about 2 g per kg body weight in the absence of active bleeding. although plasbumin-5 is to be preferred for the usual volume deficits, plasbumin-20 with appropriate crystalloids may offer therapeutic advantages in oncotic deficits or in long-standing shock where treatment has been delayed.(2) removal of ascitic flu

United States - English - NLM (National Library of Medicine)

kedrion biopharma, inc. - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 2.5 g in 50 ml - emergency treatment of hypovolemic shock albuked 5 is iso-oncotic with normal plasma and on intravenous infusion will expand the circulating blood volume by an amount approximately equal to the volume infused. in conditions associated mainly with a volume deficit, albumin is best administered as a 5% solution (albuked 5); but where there is an oncotic deficit, albumin (human) 25%, usp (albuked™ 25) may be preferred. this is also an important consideration where the treatment of the shock state has been delayed. if albuked 25 is used, appropriate additional crystalloid should be administered.(1) crystalloid solutions in volumes several times greater than that of albuked 5 may be effective in treating shock in younger individuals who have no preexisting illness at the time of the incident. older patients, especially those with preexisting debilitating conditions, or those in whom the shock is caused by a medical disorder, or where the state of shock has existed for some time before active therapy could be insti

Singapore - English - HSA (Health Sciences Authority)

euro asia medico pte. ltd. - albumin (human) - injection - 20% w/v - albumin (human) 20% w/v

United States - English - NLM (National Library of Medicine)

csl behring llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 25 g in 100 ml - albumin is indicated in the emergency treatment of shock and in other similar conditions where the restoration of blood volume is urgent. if there has been considerable loss of red blood cells, transfusion with packed red blood cells is indicated. albumin or albumin in either normal saline or dextrose is indicated to prevent marked hemoconcentration and to maintain appropriate electrolyte balance. albumin is indicated in those clinical situations usually associated with a low concentration of plasma protein and a resulting decreased circulating blood volume. although diuresis may occur soon after albumin administration has been instituted, best results are obtained if albumin is continued until the normal serum protein level is regained. albuminar® -25 may be contraindicated in patients with severe anemia or cardiac failure and in patients with a history of allergic reactions to human albumin.

United States - English - NLM (National Library of Medicine)

grifols usa, llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - emergency treatment of hypovolemic shock plasbumin-25 is hyperoncotic and on intravenous infusion will expand the plasma volume by an additional amount, three to four times the volume actually administered, by withdrawing fluid from the interstitial spaces, provided the patient is normally hydrated interstitially or there is interstitial edema.(1) if the patient is dehydrated, additional crystalloids must be given,(4) or alternatively, albumin (human) 5%, usp (plasbumin® -5) should be used. the patient’s hemodynamic response should be monitored and the usual precautions against circulatory overload observed. the total dose should not exceed the level of albumin found in the normal individual, i.e., about 2 g per kg body weight in the absence of active bleeding. although plasbumin-5 is to be preferred for the usual volume deficits, plasbumin-25 with appropriate crystalloids may offer therapeutic advantages in oncotic deficits or in long-standing shock where treatment has been delayed.(2) removal of ascitic flu

Canada - English - Health Canada

instituto grifols s.a. - albumin (human) - solution - 20% - albumin (human) 20% - blood derivatives